Drugs / Gallium-68 THP-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03617588 | Jun 2018 → Jun 2019 | prostate cancer | Theragnostics Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium-68 THP-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03617588 ↗ |
| Route | Intravenous | “Single intravenous administration of Gallium-68 THP-PSMA” NCT03617588 ↗ |